Last reviewed · How we verify
MMRV (AMP)
MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating adaptive immune responses to all four viruses.
MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating adaptive immune responses to all four viruses. Used for Prevention of measles, mumps, rubella, and varicella in children.
At a glance
| Generic name | MMRV (AMP) |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MMRV combines four live attenuated viral vaccines into a single formulation. Each component virus is weakened to trigger protective antibody and cell-mediated immune responses without causing disease. The vaccine primes the immune system to recognize and rapidly respond to natural infection with any of these four viruses.
Approved indications
- Prevention of measles, mumps, rubella, and varicella in children
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Varicella-like rash
- Parotitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMRV (AMP) CI brief — competitive landscape report
- MMRV (AMP) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI